Praxis Precision Medicines (PRAX) Shares Phase 2/3 POWER1 Study Findings

Praxis Precision Medicines Inc. (NASDAQ:PRAX) is one of the 10 most promising mid-cap healthcare stocks according to hedge funds.

On June 2, Praxis Precision Medicines Inc. (NASDAQ:PRAX) published the findings of its extensive Phase 2/3 POWER1 study. This research evaluated the effectiveness of vormatrigine as a treatment for individuals with focal onset seizures. This study comes after a thorough double-blind, placebo-controlled examination that tracked patients using up to three approved anti-seizure drugs at the same time.

Copyright: dolgachov / 123RF Stock Photo

The company has emphasized very positive effectiveness signs within the higher dose group, even if the major intended goals involving substantial reductions in monthly seizure frequency were not met. Throughout the study period, the fundamental clinical data showed a strong overall safety profile and remarkably low patient discontinuation rates.

The company states that it will carefully examine these basic trial parameters to identify the best course of action for the current POWER2 research, as well as the further development of this particular drug. In the meantime, management stressed that the company is still very much committed to carrying out the planned commercial launches of ulixacaltamide and relutrigine in order to enhance its growing product portfolio.

Praxis Precision Medicines Inc. (NASDAQ:PRAX) is involved in developing therapies to cure disorders related to the central nervous system, which are characterized by neuronal excitation-inhibition imbalance. These disorders include epilepsy, movement disorders, and depression. The company utilizes its proprietary platforms like Cerebrum and Solidus to target such imbalances.

While we acknowledge the risk and potential of PRAX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than PRAX and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1